Lung Cancer | Specialty

Immune Checkpoint Inhibitor Combinations in NSCLC

February 7th 2014

Checkpoint Inhibitor Related Pseudoprogression in NSCLC

February 7th 2014

Introduction: Checkpoint Inhibition in NSCLC

February 7th 2014

Anti-PD-1 Antibody MK-3475 Advances Into Multiple Tumor Types

February 7th 2014

Merck announced the signing of three separate clinical collaboration agreements to evaluate the potential of its investigational anti-PD-1 immunotherapy MK-3475 across multiple tumor types

Dr. Herbst on the Benefit of Targeting PD-1/PD-L1

February 4th 2014

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the unique benefit of targeting the PD-1/PD-L1 pathway in lung cancer.

Clinical Trial Changes Needed to Improve Outcomes in Stage III NSCLC

February 4th 2014

Treatment of stage III non-small cell lung cancer (NSCLC) with chemotherapy, radiation, and surgery has hit a plateau, and the key to improved outcomes will hinge on the testing of targeted therapies in clinical trials with more novel designs and better patient selection, according to a leading researcher.

The Role of Anti-PD-L1 Immunotherapy in Cancer

January 29th 2014

Immunotherapy has become an increasingly appealing therapeutic strategy for patients with cancer, with many late-stage clinical trials demonstrating overall survival (OS) advantages in melanoma and castrationresistant prostate cancer.

Dr. Rapoport Describes Samsca's Mechanism of Action

January 21st 2014

Frederick Alan Rapoport, MD, clinical instructor in the Department of Medicine at NYU Langone Medical Center, describes the mechanism and utility of Samsca (tolvaptan).

Kris Provides Insight Into New Drugs for Lung Cancer

January 16th 2014

Mark G. Kris, MD, from the Memorial Sloan-Kettering Cancer Center, describes the new drugs and other emerging trends in lung cancer.

Dr. Piperdi on Immunotherapy in Lung Cancer

January 15th 2014

Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, discusses the potential of immunotherapy for the treatment of patients with lung cancer.

Dabrafenib Receives Breakthrough Designation for NSCLC

January 13th 2014

The BRAF inhibitor dabrafenib (Tafinlar) has received a Breakthrough Therapy designation from the FDA for its potential as a treatment for patients with metastatic BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) who have received at least one prior line of platinum-containing chemotherapy.

Dr. Kris on the Challenges of Treating Lung Cancer

January 13th 2014

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses some of the challenges of treating patients with lung cancer.

"N of 1" Research: Molecular Findings Create Urgency for New Drug Discovery Paradigm

January 13th 2014

There has been considerable discussion within the oncology literature during the past several years regarding the level of evidence required to consider a new antineoplastic agent an acceptable "standard-of-care" in routine disease management.

Dr. Shaw on Crizotinib as a Standard of Care in NSCLC

January 9th 2014

Alice T. Shaw, MD, PhD, discusses how crizotinib has changed patient care over the last few years.

Dr. Rizvi on Pseudo-Progression in Lung Cancer

January 6th 2014

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses the phenomenon of pseudoprogression in patients with lung cancer after they receive immunotherapy treatment.

Making Sense of the USPSTF Recommendations on Lung Cancer Screening

January 2nd 2014

On December 30th, the United States Preventive Services Task Force (USPSTF) announced they recommend annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 55-80 years who have a 30 pack-year smoking history.

Model Emerges for Targeting Oncogenes in NSCLC

December 30th 2013

Between 2007 and 2011, a collaboration among clinical oncologists, pathologists, and industry scientists led to the identification of a new molecularly defined subset of non-small cell lung cancer, followed by the finding that crizotinib, then under development as a MET inhibitor, was an inhibitor of anaplastic lymphoma kinase.

Dr. Belani Discusses Treating NSCLC with CO-1686

December 6th 2013

Chandra P. Belani, MD, discusses CO-1686, which is currently being studied for the treatment of non-small cell lung cancer.

Dr. Herbst on PD-1 Inhibitors in Lung Cancer

November 26th 2013

Roy S. Herbst, MD, PhD, discusses the sequencing possibilities of anti-PD-1 agents in treating patients with lung cancer.

Dr. Piperdi on the Stimuvax Vaccine in Lung Cancer

November 20th 2013

Bilal Piperdi, MD, from the Albert Einstein College of Medicine, discussed a trial looking at a vaccine in patients with lung cancer at the 8th Annual New York Lung Cancer Symposium®.